Establishing the optimal dose of therapeutic zinc supplementation for the
treatment of acute diarrhoea in under five children - a dose response trial in a
South Asian and a Sub-Saharan African setting

Background /Rationale
The Zinc Therapeutic Dosage Trial (ZTDT) seeks to answer the question whether lower
dosages of zinc will increase caretakers’ willingness to utilize zinc as part of standard
diarrhoea case management. Zinc as a heavy metal is not very palatable and is associated
with excess vomiting. Current WHO technical recommendations require 20 mg of zinc. We
are testing whether lower dosages (10 mg and 5 mg) compared to the standard dosage (20
mg) are as clinically efficacious (same reduction in duration of diarrhoea) and have a lower
side effect profile (less acute vomiting after treatment).

Study Questions & Design
In a three arm randomized and blinded clinical trial we propose to determine the optimal
dose (20 mg or 10 mg or 5 mg) of therapeutic zinc supplement for the treatment of children
aged 6 – 59 months with acute diarrhoea. We will enrol 4500 study subjects (1500 subjects per
arm).

Programmatic Implications
A lower dose (5 or 10 mg) of zinc, if clinically as efficacious as the current dosage (20 mg)
and with a less frequent side effect profile, may lead to greater utilization of zinc in diarrhoea
standard case management. As zinc has been shown to reduce severity and duration
of diarrhoea this has major programmatic and health implications.

Locations & Collaborators
India
Centre for Public Health Kinetics, New Dehli (Dr. Sunil Sazawal,
Ms. Usha Dhingra)

Tanzania
University College of Health Sciences, Dar es Salaam, (Professor Karim
Manji, Muhimbili)

USA
Boston Children’s Hospital, Boston MA, (Dr Christopher Duggan)

Data Collection
December 2016 -December 2018

Funders
Bill & Melinda Gates Foundation

Web

For further information, please contact:
Per ASHORN
ashornpi@who.int

Jonathon SIMON
simonjo@who.int